Vitamin K antagonist vs direct oral anticoagulants with antiplatelet therapy in dual or triple therapy after percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation: Meta-analysis of randomized controlled trials.
Vincent RoulePierre ArdouinClément BrietAdrien LemaitreMathieu BignonRémi SabatierLaure Champ-RigotPaul MilliezKatrien BlanchartFarzin BeyguiPublished in: Clinical cardiology (2019)
Our meta-analysis supports the use of dual therapy combining a DOAC and clopidogrel as the default regimen in most AF patients after PCI and/or ACS.
Keyphrases
- acute coronary syndrome
- antiplatelet therapy
- percutaneous coronary intervention
- direct oral anticoagulants
- atrial fibrillation
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- systematic review
- acute myocardial infarction
- venous thromboembolism
- coronary artery bypass grafting
- end stage renal disease
- oral anticoagulants
- coronary artery disease
- catheter ablation
- left atrial
- ejection fraction
- newly diagnosed
- heart failure
- peritoneal dialysis
- left atrial appendage
- patient reported outcomes
- prognostic factors
- chronic kidney disease
- cell therapy
- functional connectivity
- randomized controlled trial
- case control
- resting state
- left ventricular